HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human
HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human

Immobilized HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&PRAME Antibody, hFc Tag with the EC50 of 6.1 ng/ml determined by ELISA.

HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human

The purity of HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human

HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human

PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
Z06591
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer[Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and ALYVDSLFFL peptide]
Accession # P79603(HLA-A*02:01)&P61769(B2M)&ALYVDSLFFL		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human at 1μg/ml (100μl/well) on the plate can bind Anti-HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Antibody, hFc Tag. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS, 100mM L-arginine (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human

    Immobilized HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&PRAME Antibody, hFc Tag with the EC50 of 6.1 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human

    The purity of HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human
    • HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human

    HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited.
Synonyms PRAME; OIP-4; OIP4; MAPE

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.